RNID: For deaf and hard of hearing people.

Reasons to invest

  • The number of drugs currently available as a primary indication for tinnitus is: None
  • In the USA and northern Europe the number of tinnitus sufferers is: 18.6 million
  • The product value of a novel drug bringing symptomatic relief of tinnitus is worth: $940 million
tinnitus cover

Tinnitus market report answers the following key questions:

  • What is the size of the tinnitus market and its future growth in the USA and northern Europe?
  • What are the treatment pathways?
  • Who are the leading players or competitors and how will they change in the future?
  • What are the unmet clinical needs? 
  • Which research avenues should be explored to identify potential leads?

What's the next step?

  • We can send you a free executive summary of this report.
  • We can discuss with you – face to face – how your technologies could address the needs of these markets.
  • We can foster collaboration through our extensive network of academic researchers and companies already working in this sector.

More information

Order this report by calling 020 7294 3742 or email us at research@rnid.org.uk

Order full copies of our market reports online (external link, opens new browser window) here- now FREE!